rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2010-1401rsp-1240Research ArticleСтатьиArticlesИНГИБИТОРЫ ФНО-α И ИХ ВЛИЯНИЕНА ФАКТОРЫ РИСКА ПОРАЖЕНИЯ СЕРДЕЧНО-СОСУДИСТОЙСИСТЕМЫ У ПАЦИЕНТОВ С РЕВМАТОИДНЫМ АРТРИТОМTumor necrosis factor-α inhibitors and their effects on cardiovascular risk factorsin patients with rheumatoid arthritisLinevaO GLinevaO Glinevao@mail.ru <mailto:linevao@mail.ru>ПопковаТ. В.PopkovaT V-НовиковаД. С.NovikovaD S-НасоновЕвгений ЛьвовичNasonovE L-LinevaO GLinevaO G-ПопковаТ. В.PopkovaT V-НовиковаД. С.NovikovaD S-НасоновЕвгений ЛьвовичNasonovE L-201015022010481№1 (2010)1519Copyright © Lineva O.G., Попкова Т.В., Новикова Д.С., Насонов Е.Л., Lineva O.G., Попкова Т.В., Новикова Д.С., Насонов Е.Л., 20102010Lineva O.G., Попкова Т.В., Новикова Д.С., Насонов Е.Л., Lineva O.G., Попкова Т.В., Новикова Д.С., Насонов Е.Л.Lineva O.G., Popkova T.V., Novikova D.S., Nasonov E.L., Lineva O.G., Popkova T.V., Novikova D.S., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/1240References<div><p>Hall F.C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology 2005;44:1473-82.</p><p>Goodson N.J., Wiles N.J., Lunt M. et al. Mortality in early inflammatory polyarthritis. Cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-19.</p><p>Leuven S.I., Franssen R., Kastelein J.J. et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 2008;47:3-7.</p><p>Насонов Е.Л. Иммунологические маркеры атеросклероза. Тер арх 2002;5:80-5.</p><p>Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.</p><p>Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.</p><p>Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004.</p><p>Gonzalez A., Kremers M.H., Crowson C.S. et al. Survival trends and risk factors for mortality in rheumatoid arthritis. Int J Аdv in Rheumatol 2005;3:38-46.</p><p>Radovits B.J., Popa-Diaconu D.A., Popa C. et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2008;8:10-15.</p><p>Bartoloni B.E., Marchesi S., Delle Monache F. et al. Subclinical atherosclerosis in young patients with rheumatoid arthritis and low disease activity. Rheumatismo 2005;57(1):16-21.</p><p>Vaudo G., Marchesi S., Gerli R. et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004;63(1):31-5.</p><p>Kremers M.H., Crowson C., Nicola P. et al. Increased unrecognized coronary heart disease and sudden deaths rheumatoid arthritis. A population-based controlled study. Arthritis Rheum 2005;52:402-11.</p><p>Nielen M.J., van Halm V.P., Numohamed M.T. et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthritis Rheum 2003;48:344-50.</p><p>Goodson N.J., Symmons D.P., Scott D.I. et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis. Arthritis Rheum 2005;52(8):2293-9.</p><p>Попкова Т.В., Хелковская А.Н., Мач Э.С. и др. Сердечно-сосудистые заболевания при ревматоидном артрите. Тер арх 2007;5:9-14.</p><p>Del Rincon I., Williams K., Stern M. et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48(7):1833-40.</p><p>Gonzalez-Juanatey C., Liorca J., Testa A. et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003;82:407-13.</p><p>Nagata-Sakurai M., Inaba M., Goto H. et al. Inflammation and bone resorbtion as independent factors of accelerated arterial</p><p>Kaplan M.J. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006;18(3):289-97.</p><p>Peterson M.J., Symmons D.P., McCarrey D.W. et al. Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis - EULAR TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis 2008;67(Suppl. II):310.</p><p>Choi H.K., Hernan M.A., Seeger J.D. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.</p><p>Ревматология: национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 647-60.</p><p>Кардиология: национальное руководство. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГЭОТАР-Медиа, 2007; 1232 с.</p><p>Hurliman D., Forster A., Noll G. et al. Anti-tumor necrosis factor-alfa treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7.</p><p>Gonzalez-Juanatey С., Testa A., Garcia-Castelo A. et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor-alfa antibody. Arthritis Rheum 2004;51:447-50.</p><p>Irace C., Mancuso G., Fiaschi E. et al. Effect of anti TNF alfa therapy on arterial diametr and wall shear stress and HDL cholesterol. Atherosclerosis 2004;177:113-8.</p><p>Vis M., Nurmohamed M.T., Wolbink G. et al. Short-term effects on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005;32:252-5.</p><p>Popa C., Radstake T., Netea M.G. et al. Influence of anti-tumor necrosis factor-alfa therapy on cardiovascular risk factors in patients with actiwe rheumatoid. Ann Rheum Dis 2005;64:303-5.</p><p>Popa C., Radstake T., Netea M.G. et al. Long-term anti TNF alfa therapy effect on lipoprotein concentrations in patients with actiwe rheumatoid arthritis (abstract). Arthritis Rheum 2006;54:9.</p><p>Spanakis E., Sidiropouls P., Papadakis J. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflamatory arthritides treated with Infliximab. J Rheumatol 2006;33:12.</p><p>Kiortsis D.N., Mavridis A.K. Effects of infliximab lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheum Dis 2006;33:4921-3.</p><p>Cauza E., Cauza K., Hanusch-Ensener U. et al. Intravenosus anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002;114:1004-7.</p><p>Dominguenz H., Storaard H., Rask-Madsen C. et al. Metabolic and vascular effects of tumor-alpha blockades with atanarcept in obese patients with type 2 diabetes. J Vasc Res 2005;42:517-25.</p><p>Kiortsis D.N., Mavridis A.K. Effects of infliximab on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005;64:765-6.</p><p>Gonzales-Gay M.A., De Matias J.M., Gonzalez-Juanatey C. et al. Anti-tumor factor-alpha blockade improvers insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-6.</p><p>Gonzalez-Juanatey C., Liorca J., Garcia-Porrua C. et al. Effect of anti-tumor necrosis factor-alpha therapy on the progression of subclinical aterosclerosis in severe rheumatoid arthritis. Arhritis Rheum 2006;55:150-3.</p><p>Del Porto F., Lagana B., Lai S. et al. Response to anti-tumor necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 2007;46:1111-5.</p><p>Naranjo A., Sokka T., Descalzo M.A. et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30.</p><p>Dixon W.G., Watson K.D., Lunt M. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12.</p><p>Jacobsson L.T., Askling J., Rantapaa-Dahlgvist S. Anti-TNF therapy and risk of death up to 8 years after treatment start. Results from the Swedish biologics register (ARTIS). Ann Rheum Dis 2008;67(Suppl. II):183.</p><p>Jacobsson L.T., Turesson C., Gulfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8.</p><p>Solomon D.H., Avorn J., Katz J.N. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-8.</p><p>Chung E.S., Packer M., Lo K.H. et al. Randomized, double-blind, placebo controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alfa, in patients with moderate-to-severe heart failure results of the anti-TNF Therapy Againts Congestive Heart Failure(ATTACH) trial. Circulation 2003;107:3133-40.</p><p>Kwon H.J., Cote T.R., Cuffe M.S. et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.</p></div><br /><div><p>Hall F.C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology 2005;44:1473-82.</p><p>Goodson N.J., Wiles N.J., Lunt M. et al. Mortality in early inflammatory polyarthritis. Cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-19.</p><p>Leuven S.I., Franssen R., Kastelein J.J. et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 2008;47:3-7.</p><p>Насонов Е.Л. Иммунологические маркеры атеросклероза. Тер арх 2002;5:80-5.</p><p>Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.</p><p>Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.</p><p>Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004.</p><p>Gonzalez A., Kremers M.H., Crowson C.S. et al. Survival trends and risk factors for mortality in rheumatoid arthritis. Int J Аdv in Rheumatol 2005;3:38-46.</p><p>Radovits B.J., Popa-Diaconu D.A., Popa C. et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2008;8:10-15.</p><p>Bartoloni B.E., Marchesi S., Delle Monache F. et al. Subclinical atherosclerosis in young patients with rheumatoid arthritis and low disease activity. Rheumatismo 2005;57(1):16-21.</p><p>Vaudo G., Marchesi S., Gerli R. et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004;63(1):31-5.</p><p>Kremers M.H., Crowson C., Nicola P. et al. Increased unrecognized coronary heart disease and sudden deaths rheumatoid arthritis. A population-based controlled study. Arthritis Rheum 2005;52:402-11.</p><p>Nielen M.J., van Halm V.P., Numohamed M.T. et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthritis Rheum 2003;48:344-50.</p><p>Goodson N.J., Symmons D.P., Scott D.I. et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis. Arthritis Rheum 2005;52(8):2293-9.</p><p>Попкова Т.В., Хелковская А.Н., Мач Э.С. и др. Сердечно-сосудистые заболевания при ревматоидном артрите. Тер арх 2007;5:9-14.</p><p>Del Rincon I., Williams K., Stern M. et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48(7):1833-40.</p><p>Gonzalez-Juanatey C., Liorca J., Testa A. et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003;82:407-13.</p><p>Nagata-Sakurai M., Inaba M., Goto H. et al. Inflammation and bone resorbtion as independent factors of accelerated arterial</p><p>Kaplan M.J. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006;18(3):289-97.</p><p>Peterson M.J., Symmons D.P., McCarrey D.W. et al. Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis - EULAR TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis 2008;67(Suppl. II):310.</p><p>Choi H.K., Hernan M.A., Seeger J.D. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.</p><p>Ревматология: национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 647-60.</p><p>Кардиология: национальное руководство. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГЭОТАР-Медиа, 2007; 1232 с.</p><p>Hurliman D., Forster A., Noll G. et al. Anti-tumor necrosis factor-alfa treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7.</p><p>Gonzalez-Juanatey С., Testa A., Garcia-Castelo A. et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor-alfa antibody. Arthritis Rheum 2004;51:447-50.</p><p>Irace C., Mancuso G., Fiaschi E. et al. Effect of anti TNF alfa therapy on arterial diametr and wall shear stress and HDL cholesterol. Atherosclerosis 2004;177:113-8.</p><p>Vis M., Nurmohamed M.T., Wolbink G. et al. Short-term effects on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005;32:252-5.</p><p>Popa C., Radstake T., Netea M.G. et al. Influence of anti-tumor necrosis factor-alfa therapy on cardiovascular risk factors in patients with actiwe rheumatoid. Ann Rheum Dis 2005;64:303-5.</p><p>Popa C., Radstake T., Netea M.G. et al. Long-term anti TNF alfa therapy effect on lipoprotein concentrations in patients with actiwe rheumatoid arthritis (abstract). Arthritis Rheum 2006;54:9.</p><p>Spanakis E., Sidiropouls P., Papadakis J. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflamatory arthritides treated with Infliximab. J Rheumatol 2006;33:12.</p><p>Kiortsis D.N., Mavridis A.K. Effects of infliximab lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheum Dis 2006;33:4921-3.</p><p>Cauza E., Cauza K., Hanusch-Ensener U. et al. Intravenosus anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002;114:1004-7.</p><p>Dominguenz H., Storaard H., Rask-Madsen C. et al. Metabolic and vascular effects of tumor-alpha blockades with atanarcept in obese patients with type 2 diabetes. J Vasc Res 2005;42:517-25.</p><p>Kiortsis D.N., Mavridis A.K. Effects of infliximab on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005;64:765-6.</p><p>Gonzales-Gay M.A., De Matias J.M., Gonzalez-Juanatey C. et al. Anti-tumor factor-alpha blockade improvers insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-6.</p><p>Gonzalez-Juanatey C., Liorca J., Garcia-Porrua C. et al. Effect of anti-tumor necrosis factor-alpha therapy on the progression of subclinical aterosclerosis in severe rheumatoid arthritis. Arhritis Rheum 2006;55:150-3.</p><p>Del Porto F., Lagana B., Lai S. et al. Response to anti-tumor necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 2007;46:1111-5.</p><p>Naranjo A., Sokka T., Descalzo M.A. et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30.</p><p>Dixon W.G., Watson K.D., Lunt M. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12.</p><p>Jacobsson L.T., Askling J., Rantapaa-Dahlgvist S. Anti-TNF therapy and risk of death up to 8 years after treatment start. Results from the Swedish biologics register (ARTIS). Ann Rheum Dis 2008;67(Suppl. II):183.</p><p>Jacobsson L.T., Turesson C., Gulfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8.</p><p>Solomon D.H., Avorn J., Katz J.N. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-8.</p><p>Chung E.S., Packer M., Lo K.H. et al. Randomized, double-blind, placebo controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alfa, in patients with moderate-to-severe heart failure results of the anti-TNF Therapy Againts Congestive Heart Failure(ATTACH) trial. Circulation 2003;107:3133-40.</p><p>Kwon H.J., Cote T.R., Cuffe M.S. et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.</p></div><br />
The authors declare that there are no conflicts of interest present.